TITLE

Metformin's contraindications: needed for now

AUTHOR(S)
Fantus, I. George
PUB. DATE
August 2005
SOURCE
CMAJ: Canadian Medical Association Journal;8/30/2005, Vol. 173 Issue 5, p505
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents views on whether contraindications to metformin therapy are warranted for certain patients with type 2 diabetes. Effectiveness in the treatment of type 2 diabetes; Background on case reports showing the occurrence of lactic acidosis among diabetic patients taking metformin; Drugs that can lower blood glucose concentrations in patients with contraindications to metformin.
ACCESSION #
17961357

 

Related Articles

  • Metformin's contraindications should be contraindicated. McCormack, James; Johns, Kevin; Tildesley, Hugh // CMAJ: Canadian Medical Association Journal;8/30/2005, Vol. 173 Issue 5, p502 

    Offers views on whether contraindications to metformin therapy are warranted for certain patients with type 2 diabetes. Contraindications to the use of metformin listed in the "Compendium of Pharmaceuticals and Specialties"; Benefits of metformin use; Risk of lactic acidosis among patients who...

  • Metformin.  // Reactions Weekly;9/27/2008, Issue 1221, p23 

    The article describes the case of a 64-year-old woman who developed lactic acidosis while being treated with metformin for type 2 diabetes mellitus. The woman, who had a history of hypertension and mild chronic renal failure, underwent gynaecological surgery and developed oliguria, confusion,...

  • Canagliflozin.  // AHFS Consumer Medication Information;Feb2017, p1 

    Canagliflozin is used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in patients with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Canagliflozin is in a class of...

  • Diabetic Ketoacidosis and Related Events in the Canaglif lozin Type 2 Diabetes Clinical Program. Erondu, Ngozi; Desai, Mehul; Ways, Kirk; Meininger, Gary // Diabetes Care;Sep2015, Vol. 38 Issue 9, p1680 

    OBJECTIVE This study assessed the incidence of serious adverse events of diabetic ketoacidosis (DKA) among patients with type 2 diabetes treated with canagliflozin. RESEARCH DESIGN AND METHODS All serious adverse events of DKA and related events (ketoacidosis, metabolic acidosis, and acidosis)...

  • Pharma: Clinic Roundup.  // BioWorld Today;7/31/2012, Vol. 23 Issue 147, p7 

    The article reports that analyses have shown that Onglyza (saxagliptin) from Bristol-Myers Squibb Co. and AstraZeneca plc resulted to improvements across key measures of blood sugar control in adults with type II diabetes who are at high risk for cardiovascular disease.

  • Clinical Pharmacokinetics of Troglitazone. Loi, C-M.; Young, M.; Randinitis, E.; Vassos, A.; Koup, J.R. // Clinical Pharmacokinetics;1999, Vol. 37 Issue 2, p91 

    Troglitazone is a new thiazolidinedione oral antidiabetic agent approved for use to improve glycaemic control in patients with type 2 diabetes. It is rapidly absorbed with an absolute bioavailability of between 40 and 50%. Food increases the absorption by 30 to 80%. The pharmacokinetics of...

  • Alogliptin.  // AHFS Consumer Medication Information;Feb2017, p1 

    Alogliptin is used along with diet and exercise to lower blood sugar levels in patients with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Alogliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4)...

  • Metformin: no evidence of increased lactic acidosis risk.  // Reactions Weekly;1/24/2004, Issue 985, p5 

    Discusses research being done on the risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Reference to a study by S. R. Salpeter et al published in the November 24, 2003 issue of the "Archives of Internal Medicine"; Comparison between the risk of lactic...

  • Review: Metformin does not increase fatal or nonfatal lactic acidosis or blood lactate levels in type 2 diabetes mellitus. Sigal, Ronald J. // ACP Journal Club;Nov/Dec2002, Vol. 137 Issue 3, p88 

    Discusses research being done on the impact of metformin on the risk for fatal and nonfatal lactic acidosis or blood lactate levels in patients with type 2 diabetes mellitus. Reference to study by S. Salpeter and colleagues; Analysis of various studies on metformin; Conclusion.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics